Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Microfocused Ultrasound for Facial Pigmentary Diseases and Rosacea

25. Juni 2026 aktualisiert von: Jian dan, Xiangya Hospital of Central South University

A Prospective, Randomized, Sham-controlled, Assessor-blinded, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of Microfocused Ultrasound in Patients With Facial Pigmentary Diseases and Rosacea

This clinical study will evaluate the efficacy and safety of microfocused ultrasound treatment in patients with facial pigmentary diseases and rosacea.

The study includes two independent disease cohorts: a facial pigmentary disease cohort and a rosacea cohort. Participants in each cohort will be randomly assigned to receive either active microfocused ultrasound treatment or sham stimulation. Sham stimulation will follow the same treatment procedure as active treatment but will not deliver effective therapeutic ultrasound energy.

Participants will receive one treatment session per month for 6 months and will be followed for up to 12 months. The study will assess changes in clinical severity scores, digital skin imaging parameters, patient-reported symptoms, quality of life, and safety outcomes, including adverse events.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a prospective, randomized, sham-controlled, assessor-blinded, parallel-group clinical study designed to evaluate the efficacy and safety of microfocused ultrasound in patients with facial pigmentary diseases and rosacea.

The study consists of two independent disease cohorts. The facial pigmentary disease cohort will include participants with eligible facial pigmentary disorders, such as melasma, periorbital hyperpigmentation, melanosis, and lichen planus pigmentosus. The rosacea cohort will include participants who meet the diagnostic criteria for rosacea. Each cohort will be randomized separately in a 1:1 ratio to either the active microfocused ultrasound group or the sham stimulation control group.

Participants assigned to the active treatment group will receive microfocused ultrasound treatment once monthly for 6 months. The planned treatment parameters include a power range of 3.76 to 5.12 W and a frequency of 8 Hz, with each session stopped after the preset treatment endpoint is reached. Participants assigned to the sham stimulation group will undergo the same procedure, including use of ultrasound coupling gel, probe contact, treatment environment, and treatment duration, but without delivery of effective therapeutic energy.

Efficacy assessments will include investigator-assessed clinical severity scores, patient-reported outcome measures, VISIA digital skin analysis, dermatology-related quality of life assessment, and psychological symptom assessment. Safety will be evaluated through physical examination, vital signs, and monitoring of adverse events and serious adverse events throughout the study.

An exploratory tissue sample substudy may be conducted in participants who voluntarily provide additional informed consent. This substudy is exploratory and will not affect participation in the main study or the primary efficacy analysis.

Studientyp

Interventionell

Einschreibung (Geschätzt)

200

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • China
    • Hunan
      • Changsha, Hunan, China, 410083
        • Xiangya Hospital, Central South University

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  1. Male or female participants aged 20 to 60 years.
  2. Diagnosed by the investigator as having facial pigmentary disease or rosacea eligible for this study.
  3. Participants with rosacea must meet the diagnostic criteria of the Chinese Guideline for the Diagnosis and Treatment of Rosacea (2021 edition).
  4. Participants with facial pigmentary diseases must be diagnosed by two dermatologists with associate senior professional title or above, based on clinical manifestations and, when necessary, auxiliary examinations such as Wood's lamp examination, dermoscopy, or skin histopathology. Eligible pigmentary diseases may include melasma, periorbital hyperpigmentation, melanosis, lichen planus pigmentosus, or other facial pigmentary diseases considered suitable for this study.
  5. The skin lesions are suitable for microfocused ultrasound treatment and follow-up assessment.
  6. Able to comply with study treatment, follow-up visits, photography, and related assessments during the study.
  7. Able to understand the study procedures, voluntarily participate in the study, and sign written informed consent.

Exclusion Criteria:

  1. Pregnant or lactating women, or women planning to become pregnant during the study period.
  2. Known allergy to ultrasound coupling gel or any of its excipients.
  3. Presence of other obvious active inflammatory skin diseases, infectious skin diseases, or other facial skin conditions that may affect efficacy evaluation, apart from the target disease of this study.
  4. Use within 1 month before screening of topical medications or procedures that may affect study evaluation, including but not limited to corticosteroids, calcineurin inhibitors, depigmenting agents, or energy-based treatments.
  5. Severe cardiac, hepatic, renal, or other important organ dysfunction, or other severe systemic diseases that, in the investigator's judgment, may affect the safety or efficacy evaluation of this study.
  6. Participation in another clinical trial within 30 days before screening.
  7. History of prolonged intense sun exposure within 1 month before screening, or expected inability to avoid significant sun exposure or outdoor exposure during the study period, which may affect study evaluation.
  8. Any other condition that, in the investigator's judgment, makes the participant unsuitable for this study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Active Microfocused Ultrasound - Pigmentary Disease Cohort
Participants with facial pigmentary diseases will receive active microfocused ultrasound treatment once monthly for 6 months.
Gerät: Microfocused Ultrasound Treatment
Active microfocused ultrasound treatment will be administered using an ultrasound therapy device. Treatment parameters are planned as power 3.76 to 5.12 W and frequency 8 Hz. Each treatment session will stop when the preset treatment endpoint. Treatment will be performed once monthly for 6 months.
Schein-Komparator: Sham Stimulation - Pigmentary Disease Cohort
Participants with facial pigmentary diseases will receive sham stimulation once monthly for 6 months. The sham procedure will follow the same treatment process as active treatment, including use of ultrasound coupling gel, probe contact, treatment environment, and treatment duration, but without delivery of effective therapeutic ultrasound energy.
Gerät: Sham Microfocused Ultrasound Stimulation
Sham stimulation will use the same procedure as active microfocused ultrasound treatment, including ultrasound coupling gel, probe contact, treatment environment, and treatment duration, but will not deliver effective therapeutic ultrasound energy.
Experimental: Active Microfocused Ultrasound - Rosacea Cohort
Participants with rosacea will receive active microfocused ultrasound treatment once monthly for 6 months.
Gerät: Microfocused Ultrasound Treatment
Active microfocused ultrasound treatment will be administered using an ultrasound therapy device. Treatment parameters are planned as power 3.76 to 5.12 W and frequency 8 Hz. Each treatment session will stop when the preset treatment endpoint. Treatment will be performed once monthly for 6 months.
Schein-Komparator: Sham Stimulation - Rosacea Cohort
Participants with rosacea will receive sham stimulation once monthly for 6 months. The sham procedure will follow the same treatment process as active treatment, including use of ultrasound coupling gel, probe contact, treatment environment, and treatment duration, but without delivery of effective therapeutic ultrasound energy.
Gerät: Sham Microfocused Ultrasound Stimulation
Sham stimulation will use the same procedure as active microfocused ultrasound treatment, including ultrasound coupling gel, probe contact, treatment environment, and treatment duration, but will not deliver effective therapeutic ultrasound energy.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change From Baseline in Melasma Area and Severity Index-Based Pigment Area and Severity Score at Month 6
Zeitfenster: Baseline to Month 6
Change from baseline to Month 6 in the Melasma Area and Severity Index (MASI)-based pigment area and severity score in the pigmentary disease cohort. The score assesses lesion area, darkness, and homogeneity across facial regions. Total scores range from 0 to 48, with higher scores indicating more severe pigmentation.
Baseline to Month 6
Change From Baseline in Clinician's Erythema Assessment Score at Month 6
Zeitfenster: Baseline to Month 6
Change from baseline to Month 6 in the Clinician's Erythema Assessment (CEA) score in the rosacea cohort. The CEA score ranges from 0 to 4, where 0 indicates clear or no erythema and 4 indicates severe erythema. Higher scores indicate more severe erythema.
Baseline to Month 6

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change From Baseline in Melasma Area and Severity Index-Based Pigment Area and Severity Score at Months 2, 4, and 12
Zeitfenster: Baseline to Months 2, 4, and 12
Change from baseline to Months 2, 4, and 12 in the Melasma Area and Severity Index (MASI)-based pigment area and severity score in the pigmentary disease cohort. The score assesses lesion area, darkness, and homogeneity across facial regions. Total scores range from 0 to 48, with higher scores indicating more severe pigmentation.
Baseline to Months 2, 4, and 12
Change From Baseline in Melasma Quality of Life Scale Score
Zeitfenster: Baseline to Months 6 and 12
Change from baseline in the Melasma Quality of Life Scale score in the pigmentary disease cohort. The scale contains 10 items scored from 1 to 7. Total scores range from 10 to 70, with higher scores indicating worse health-related quality of life and greater disease impact.
Baseline to Months 6 and 12
Change From Baseline in Clinician's Erythema Assessment Score at Months 2, 4, and 12
Zeitfenster: Baseline to Months 2, 4, and 12
Change from baseline to Months 2, 4, and 12 in the Clinician's Erythema Assessment (CEA) score in the rosacea cohort. The CEA score ranges from 0 to 4, where 0 indicates clear or no erythema and 4 indicates severe erythema. Higher scores indicate more severe erythema.
Baseline to Months 2, 4, and 12
Change From Baseline in Patient-Assessed Flushing Severity Score in the Rosacea Cohort
Zeitfenster: Baseline to Months 6 and 12
Change from baseline in patient-assessed flushing severity score in the rosacea cohort. Flushing is assessed using the rosacea clinical study patient assessment form. Scores range from 0 to 4, where 0 indicates none and 4 indicates always present. Higher scores indicate more frequent or more severe flushing.
Baseline to Months 6 and 12
Change From Baseline in Patient- and Investigator-Assessed Rosacea Clinical Symptom Severity Scores
Zeitfenster: Baseline to Months 6 and 12
Change from baseline in patient- and investigator-assessed rosacea clinical symptom severity scores. Patient-assessed symptoms are evaluated using the rosacea clinical study patient assessment form, and investigator-assessed signs are evaluated using the rosacea clinical study investigator assessment form. Each item is scored from 0 to 4. For patient-assessed items, 0 indicates none and 4 indicates always present. For investigator-assessed items, 0 indicates clear or none and 4 indicates severe. Higher scores indicate more severe rosacea symptoms or signs.
Baseline to Months 6 and 12
Change From Baseline in Dermatology Life Quality Index Score
Zeitfenster: Baseline to Months 6 and 12
Change from baseline in the Dermatology Life Quality Index (DLQI) score. The DLQI is a 10-item questionnaire assessing dermatology-related quality of life. Total scores range from 0 to 30, with higher scores indicating greater impairment in quality of life.
Baseline to Months 6 and 12
Change From Baseline in Patient Health Questionnaire-9 Score
Zeitfenster: Baseline to Months 6 and 12
Change from baseline in the Patient Health Questionnaire-9 (PHQ-9) score. The PHQ-9 contains 9 items, each scored from 0 to 3. Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.
Baseline to Months 6 and 12

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of Adverse Events and Serious Adverse Events
Zeitfenster: Baseline through Month 12
Incidence of adverse events, serious adverse events, and treatment-related local reactions, including facial numbness and skin pain.
Baseline through Month 12

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Xiangya Hospital of Central South University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Oktober 2025

Primärer Abschluss (Geschätzt)

1. Juli 2026

Studienabschluss (Geschätzt)

1. September 2026

Studienanmeldedaten

Zuerst eingereicht

20. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

20. Juni 2026

Zuerst gepostet (Tatsächlich)

25. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

30. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

25. Juni 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 202509103

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data will not be publicly shared due to participant privacy protection, the sensitive nature of facial images and clinical dermatology data, and institutional data management requirements. De-identified aggregate results may be reported in scientific publications.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Rosazea

Klinische Studien zur Microfocused Ultrasound Treatment

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Kosovo

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren